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Abstract 
 
Background and purpose 
Naturally occurring dysfunction in NaV channels results in complex disorders such as chronic 
pain, making these channels an attractive target for new therapies. In the pursuit of novel NaV 
modulators, we investigated spider venoms for new inhibitors of NaV channels. 
 
Experimental Approach 
We used high-throughput screens to identify a NaV modulator in venom of the spider Davus 
fasciatus. Further characterization of this venom peptide was undertaken using fluorescent 
and electrophysiological assays, molecular modeling and a rodent pain model. 
 
Key Results 
We identified a potent NaV inhibitor named μ-TRTX-Df1a. This 34-residue peptide fully 
inhibited responses mediated by NaV1.7 endogenously expressed in SH-SY5Y cells. Df1a 
also inhibited CaV3 currents but had no activity against KV2. The modelled structure of Df1a, 
which contains an inhibitor cystine knot motif, is reminiscent of the NaV channel toxin 
ProTx-I. Electrophysiology revealed that Df1a inhibits all NaV subtypes tested (hNaV1.1–
1.7). Df1a also slowed fast inactivation of NaV1.1, NaV1.3 and NaV1.5, and modified the 
voltage-dependence of activation and inactivation of most NaV subtypes. Df1a preferentially 
binds to the domain II voltage-sensor and has additional interactions with the voltage sensors 
domains III and IV, which likely explains its modulatory features. Df1a was analgesic in 
vivo, reversing the spontaneous pain behaviors induced by the NaV activator OD1. 
 
Conclusion and Implication 
μ-TRTX-Df1a shows potential as a new molecule for the development of therapies to treat 
voltage-gated ion channels mediated pain disorders. 
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Abbreviations: ACN, acetonitrile; CaV, voltage-gated calcium channel; DIEA, N, N-
diisopropylethylamine; DMF, N, N-dimethylformamide; FLIPR, Fluorescence imaging plate 
reader; HBTU, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate; 
ICK, inhibitor cysteine knot; KV, voltage-gated potassium channel; NaV, voltage-gated 
sodium channel; MALDI-TOF, Matrix-assisted laser desorption/ionization time of flight; RP-
HPLC, reversed-phase high-performance liquid chromatography; TFA, trifluoroacetic acid; 
TIPS, triisopropylsilane. 
 
Pharmacological nomenclature 
Targets: CaV3.1, CaV3.2, CaV3.3, KV2.1, NaV1.1, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, 
NaV1.7, NaV1.8 and NaV1.9. 
Ligands: Veratridine. 
 
 
1. Introduction   
 
Animal venoms have evolved into potent neurotoxins for predation and defense that cause 
harmful neurologic alterations in insects and mammals (King & Hardy, 2013; Klint et al., 
2012). These effects are induced by molecules acting on ion channels involved in the 
generation and transmission of electrical signals in neurons and muscles, which play a key 
role in several biological processes. The potency and ion channel selectivity of these 
neurotoxins have made them powerful pharmacological tools as well as therapeutic leads for 
treating channelopathy-related disorders. These include conditions such as neuropathic pain, 
epilepsy and arrhythmia, which often involve dysfunction of voltage-gated sodium (NaV) 
channel (Catterall et al., 2010; Remme & Bezzina, 2010; Rogers et al., 2006). 
 
NaV channels are glycosylated transmembrane proteins involved in action potential 
generation and propagation in excitable cells. In mammals, the NaV channel family is 
composed of nine subtypes (NaV1.1–NaV1.9) that differ in their α-subunit sequences and their 
pharmacological and functional properties. Alterations in NaV channel function and/or 
expression underlines a variety of disorders including chronic pain (Lauria et al., 2014; 
Moldovan et al., 2013). In particular, NaV1.3, NaV1.7, NaV1.8 and NaV1.9 have been strongly 
implicated in chronic pain (Liu & Wood, 2011). Expression of NaV1.3, NaV1.8 and NaV1.9 is 
altered during neuropathic pain (Dib-Hajj et al., 1999), while individuals lacking NaV1.7 
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function exhibit a congenital insensitivity to pain, with no other sensory abnormalities apart 
from anosmia (Cox et al., 2006). Several epileptic conditions are due to mutation or altered 
expression of NaV1.1 and NaV1.2 (Meisler & Kearney, 2005), and numerous anticonvulsants 
act on NaV channels by stabilizing their fast inactivation or slow-inactivated states (Errington 
et al., 2008; Ragsdale & Avoli, 1998). Other conditions such as congenital paramytonia and 
Brugada syndrome also present alterations in NaV channels (NaV1.4 and NaV1.5, 
respectively) (Amin et al., 2010; Zhao et al., 2012). Thus, NaV channels are common targets 
for the development of drugs to treat complex disorders. 
 
Several neurotoxins sourced from animal venoms have been described as modulators of NaV 
channels (Herzig et al., 2011; Kaas et al., 2012). Most have high potency at NaV channels but 
lack selectivity for the relevant therapeutic targets and cause side effects and even death at 
low doses. Spider-venom peptides have shown promising selectivity for NaV subtypes 
involved in pain pathways (Klint et al., 2015) and they have been used as leads in the search 
for new analgesics.  Using fluorescence assays and either endogenously or heterologously 
expressed NaV subtypes (Cardoso et al., 2015; Vetter et al., 2012), we have begun to 
systematically identify and characterize peptidic NaV channel modulators from spider crude 
venoms. In the present work, we describe the isolation and characterization of a new ion 
channel inhibitor (Df1a) from the tarantula Davus fasciatus using a high-throughput 
fluorescence screen. Df1a (μ-TRTX-Df1a) potently inhibits hNaV and hCaV3 channels. 
Interestingly, Df1a displays a novel dual modulation for specific hNaV subtypes, 
simultaneously inhibiting peak current and slowing fast inactivation, and reversed pain 
behaviors induced by intraplantar OD1 activation of NaV in mice. 
 
2. Material and Methods 
 
2.1 Animals 
For behavioral assessment, we used adult male C57BL/6J mice aged 6–8 weeks weighing 
20–25 g. Mice were housed in groups of 3–4 per cage, under 12 h light-dark cycle, with 
standard rodent chow and water provided ad libitum.  
 
2.2 Ethics Statement 
Ethical approval for in vivo experiments was obtained from The University of Queensland 
Animal Ethics Committee (AEC Approval Number IMB/PACE/326/15). Experiments 
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involving animals were conducted in accordance with the Animal Care and Protection 
Regulation Qld (2012), the Australian Code of Practice for the Care and Use of Animals for 
Scientific Purposes, 8th edition (2013) and the International Association for the Study of Pain 
Guidelines for the Use of Animals in Research. 
 
2.3 Cell culture 
The human neuroblastoma cell line SH-SY5Y was maintained at 37°C in a humidified 5% 
CO2 incubator in Roswell Park Memorial Institute (RPMI) medium supplemented with 15% 
fetal bovine serum (FBS) and 2 mM L-glutamine. Human Embryonic Kidney (HEK 293) 
cells expressing recombinant hNaV subtypes co-expressed with β1 auxiliary subunits (SB 
Drug Discovery, Glasgow, UK) were maintained at 37°C in a humidified 5% CO2 incubator 
in Minimal Essential medium supplemented with 10% FBS, 100 units mL
–1
 penicillin and 
100 μg mL–1 streptomycin, 2 mM L-glutamine and variable concentrations of blasticidin, 
geneticin and zeocin according to manufacturer’s protocols. Replicating cells were sub-
cultured every 3–4 days in a 1:5 ratio using 0.25% trypsin/EDTA. Chinese hamster ovarian 
(CHO) cells expressing recombinant hNaV1.6 channels (EZ cells, ChanTest Corp, OH, USA) 
were maintained at 37°C in a humidified 5% CO2 incubator in F-12 medium supplemented 
with 10% FBS, 100 U mL
–1
 penicillin and 100 μg mL–1 streptomycin. 
 
2.4 Venom fractionation 
Venom from Davus fasciatus was obtained by electrical stimulation as previously described 
(Herzig & Hodgson, 2009). Dried venom (1 mg) was dissolved in 100 μl Milli-Q water 
containing 0.05% trifluoroacetic acid (TFA) (Auspep, VIC, AU) and 5% acetonitrile (ACN) 
and centrifuged at 14,000 rpm for 10 min to remove particulates. Venom was fractionated by 
reversed-phase high performance liquid chromatography (RP-HPLC) using a C18 column 
(Vydac 4.6 mm x 250 mm, 5 μm, Grace Discovery Sciences, USA) with a gradient of solvent 
B (90% ACN in 0.045% TFA) in solvent A (0.05% TFA). The gradient was 5% B for 5 min, 
followed by 20 to 40% solvent B over 60 min at a flow rate 0.7 mL min
–1
. Peaks were 
collected at 0.7 mL per well and fractions were lyophilized before storage at –20°C. 
 
2.5 Screening against hNaV1.7 
Venom fractions were screened for inhibition of hNaV1.7 as previously described (Cardoso et 
al., 2015). Briefly, SH-SY5Y cells were plated at 40,000 cells per well in 384-well flat clear-
bottom black plates (Corning, NY, USA) and cultured at 37°C in a humidified 5% CO2 
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incubator for 48 h. Cells were loaded with 20 μl per well Calcium 4 dye (Molecular Devices) 
reconstituted in assay buffer containing (in mM) 140 NaCl, 11.5 glucose, 5.9 KCl, 1.4 
MgCl2, 1.2 NaH2PO4, 5 NaHCO3, 1.8 CaCl2 and 10 HEPES pH 7.4 and incubated for 30 min 
at 37°C in a humidified 5% CO2 incubator. Fluorescence responses were recorded using 
excitation at 470–495 nm and emission at 515–575 nm for 10 s to set the baseline, then 600 s 
after addition of 10% venom fraction/well and for a further 300 s after co-addition of 3 μM 
veratridine and 30 nM OD1. 
 
2.6 Mass spectrometry and peptide sequencing 
Peptide masses were determined by matrix-assisted laser desorption ionization-time of flight 
mass spectrometry (MALDI-TOF MS) using a 4700 Proteomics Bioanalyser Model (Applied 
Biosystems, CA, USA). Df1a was dissolved in water mixed 1:1 (v/v) with α-cyano-4-
hydroxy-cinnamic acid matrix (7 mg mL
–1
 in 50% ACN) and mass spectra acquired in 
positive reflector mode. The reported molecular weight of Df1a is for the monoisotopic 
M+H
+ 
ion. N-terminal sequencing was outsourced to the Australian Proteome Analysis 
Facility, Sydney, Australia. Briefly, the peptide was dissolved in urea (4 M) and ammonium 
bicarbonate (50 mM) and reduced with dithiothreitol (100 mM) at 56°C for 1 h under argon. 
The sample was then alkylated using acrylamide (220 mM) for 0.5 h in the dark. The reaction 
was quenched by the addition of excess dithiothreitol. After desalting by RP-HPLC, the 
collected fraction was loaded onto pre-cycled bioprene discs and subjected to 34 cycles of 
Edman degradation N-terminal sequencing using an ABI 494 Procise Protein Sequencing 
System (Applied Biosystems).  
 
2.7 Solid phase synthesis of Df1a 
Solvents for RP-HPLC consisted of 0.05% TFA/H2O (Solvent A) and 90% ACN/0.043% 
TFA/H2O (Solvent B). Analytical HPLC was performed on a Shimadzu LC20AT system 
using a Thermo Hypersil GOLD 2.1 x 100 mm C18 column heated at 40C with a flow rate 
of 0.3 mL min
–1
 and a gradient of 10 to 55% B over 30 min unless otherwise stated. The 
eluent was monitored at 214 nm unless otherwise stated. Preparative HPLC was performed 
on a Vydac 218TP1022 column running at a flow rate of 16 mL min
–1
 using a gradient of 10 
to 50% B over 40 min. Mass spectrometry was performed on an API2000 (ABI Sciex) mass 
spectrometer in positive ion mode. Df1a-NH2 and Df1a-OH were chain assembled on a 
Symphony (Protein Technologies Inc., AZ, USA) automated peptide synthesizer on Rink-
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amide (loading 0.67 mmol g
–1
) and Fmoc-Phe-Wang (loading 0.70 mmol g
–1
) polystyrene 
resins, respectively, on a 0.1 mmol scale. Fmoc deprotections were achieved using 30% 
piperidine DMF (1  1.5 min, then 1  4 min). Couplings was performed in DMF using 5 
equivalents of Fmoc-amino acid/HBTU/DIEA (1:1:1) relative to resin loading for 2  20 min. 
Amino acid side-chains were protected as follows: Asp(OtBu), Arg(Pbf), Cys(Trt), Gln(Trt), 
Glu(OtBu), His(Trt), Lys(Boc), Ser(tBu), Thr(tBu), Trp(Boc). Cleavage from the resin and 
removal of side-chain protecting groups was achieved by treatment with 95% TFA/2.5% 
TIPS/2.5% H2O at room temperature for 2 h. After most of the cleavage solution was 
evaporated under a stream of N2, the products were precipitated and washed with cold Et2O 
and lyophilized from 50% ACN / 0.1% TFA / H2O.  Df1a-NH2: 192 mg; ESI-MS (m/z): calc. 
(avg) 1362.6 Da [M+3H]
3+
, found 1362.3 Da. The crude product was purified by preparative 
HPLC to give 50 mg of hexathiol Df1a-NH2. Df1a-OH: 204 mg; ESI-MS (m/z): calc. (avg) 
1362.9 Da [M+3H]
3+
, found 1362.7 Da. The crude product was purified by preparative HPLC 
to give 50 mg of hexathiol Df1a-OH. 
 
2.8 Oxidative folding 
Purified reduced peptide (10 mg of Df1a-NH2 or Df1a-OH), reduced glutathione (100 equiv.) 
and oxidized glutathione (10 equiv.) were dissolved in 6M guanidine HCl (33 mL) then 
added to a solution of 0.1 M Tris (pH 8.0, 67 mL) and stirred at 4C with exposure to air for 
4 days. The major products were isolated by preparative HPLC. Df1a-NH2: 2.9 mg; ESI-MS 
(m/z): calc. (avg) 1360.6 Da [M+3H]
3+
, found 1360.4 Da. Df1a-OH: 2.5 mg; ESI-MS (m/z): 
calc. (avg) 1360.9 Da [M+3H]
3+
, found 1360.5 Da. 
 
2.9 Patch-clamp electrophysiology in mammalian cells 
NaV channels experiments were recorded in HEK 293 (SB Drug Discovery) cells expressing 
specific hNaV subtypes co-expressed with the β1 auxiliary subunit or CHO expressing hNaV 
subtypes (EZ cells, ChanTest Corp) and Na
+
 currents measured by whole-cell patch clamp 
using the automated system QPatch 16X (Biolin Scientific A/S, Ballerup, Denmark). The 
extracellular solution comprised (in mM) 1 CaCl2, 1 MgCl2, 5 HEPES, 3 KCl, 140 NaCl, 0.1 
CdCl2 and 20 TEA-Cl at pH 7.3 and 320 mOsm, and the intracellular solution comprised (in 
mM) 140 CsF, 1/5 EGTA/CsOH, 10 HEPES and 10 NaCl at pH 7.3 and 320 mOsm. The 
elicited currents were sampled at 25 kHz and filtered at 4 kHz. The average seal, whole-cell 
and chip resistances values were (in MΩ) 3690, 997 and 2.08, respectively. Cells with less 
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than 1 nA of peak Na
+
 current were not used in this study. Cells were maintained at a holding 
potential –80 mV and Na+ currents elicited by 20 ms voltage steps to 0 mV from a –120 mV 
conditioning pulse applied for 200 ms. To obtain concentration–response curves, cells were 
incubated for 5 min with increasing concentrations of Df1a. For on-rate experiments, Na
+
 
currents were measured at 15 s intervals over 15 min immediately following addition of Df1a 
at correspondent IC50 and 10x IC50 concentrations for the NaV subtypes analyzed. For off-rate 
measurements, cells were incubated for 10 min with Df1a at correspondent IC50 
concentrations for the NaV subtypes analyzed and Na
+
 currents assessed at 5-min intervals 
during saline washes. The Kon, Koff and Kd were calculated using Kd = Koff/Kon (nM), where 
Koff = 1/τoff (s
–1
) and Kon = (1/τon - Koff)/[toxin] (nM
–1
S
–1
). Voltage-activation relationships 
were obtained by measuring steady-state Na
+
 currents elicited by step depolarizations from –
110 to +80 mV using 10 mV increments. The peak conductance (GNa) was calculated from G 
= I/(V-Vrev), where I, V and Vrev represent the current value, membrane potential and reverse 
potential, respectively. The voltage of steady-state fast inactivation was estimated using a 
double-pulse protocol with currents elicited by a 20 ms depolarizing potential of 0 mV 
following a 500 ms pre-pulse to potentials from –130 to –10 mV using 10 mV increments. 
Voltage-dependence of activation and inactivation relationships was examined either in the 
absence and presence of Df1a (5 min exposure) with the cells before application of the 
voltage protocols. CaV3 channels experiments were recorded in CHO cells expressing 
hCaV3.1 and HEK 293 cells expressing hCaV3.2 and hCaV3.3 (these cell lines were kindly 
donated by Prof Emmanuel Bourinet from the Institute of Functional Genomics, Montpellier 
University, FR and Prof Edward Perez-Reyes from the School of Medicine, University of 
Virginia, USA) and Ca
+2
 currents measured by whole-cell patch clamp using an automated 
system QPatch 16X. The extracellular solution comprised (in mM) 5 CaCl2, 0.5 MgCl2, 10 
HEPES and 157 TEA-Cl at pH 7.3 and 320 mOsm, and the intracellular solution comprised 
(in mM) 140 CsF, 1 EGTA, 10 HEPES and 10 NaCl at pH 7.3 and 320 mOsm. The elicited 
currents were sampled at 25 kHz and filtered at 4 kHz. The average seal, whole-cell and chip 
resistances values were (in MΩ) 5000, 1953 and 2.2 for CHO and 1536, 734 and 2.1 for HEK 
293, respectively. Cells were maintained at a holding potential –90 mV and Ca+2 currents 
elicited by 60 ms voltage steps to -30 mV from a –120 mV conditioning pulse applied for 60 
ms. To obtain concentration–response curves, cells were incubated for 5 min with increasing 
concentrations of Df1a. All experimental data was analyzed using QPatch Assay Software 
v5.0 (Biolin Scientific A/S).  
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2.10 Determination of Df1a binding sites on hNaV1.7 
hNaV1.7/rKV2.1 chimeras containing the S3 and S4 loop and helices of the hNaV1.7 paddle 
were generated previously (Klint et al., 2015). Xenopus laevis oocytes were injected with 
cRNA encoding hNaV1.7/rKV2.1 chimera or rKV2.1. Two-electrode voltage clamp 
electrophysiology (Axoclamp 900A, Molecular Devices; 40 μL recording chamber) was used 
to measure currents 1–4 days after cRNA injection and incubation at 17°C in ND96 that 
contained (in mM) 96 NaCl, 2 KCl, 5 HEPES, 1 MgCl2, 1.8 CaCl2 and 50 μg mL
–1 
gentamycin, pH 7.6. Data were filtered at 4 kHz and digitized at 20 kHz using pClamp 
software (Molecular Devices). Micro-electrode resistances were 0.5–1 MΩ when filled with 3 
M KCl. The external recording solution contained (in mM) 50 KCl, 50 NaCl, 5 HEPES, 1 
MgCl2, 0.3 CaCl2, pH 7.6 with NaOH. Experiments were performed at room temperature 
(∼22 °C). Toxin samples were diluted in recording solution with 0.1% BSA. Potassium 
currents were elicited by depolarization to +70 mV from a holding potential of –90 mV (–120 
mV for the DIII chimera), with a tail voltage at –60 mV (–90 mV for the DIII chimera). Leak 
and background conductance, identified by blocking channels with agitoxin-2, were 
subtracted for all experiments.  
 
2.11 Activity of Df1a in vivo 
The efficacy of Df1a to inhibit NaV induced pain in vivo was assessed in mice using the α-
scorpion toxin OD1 as previously described (Cardoso et al., 2015; Deuis et al., 2016). To 
induce spontaneous pain behaviors, the NaV activator OD1 (300 nM) ± Df1a-OH (10 μM, 1 
μM) or Df1a-NH2 (10 μM, 1 μM) was administered by intraplantar injection into the left hind 
paw of mice in phosphate buffered saline containing 0.1% BSA and volume of 40 μL under 
2% isoflurane anaesthesia. Mice were then placed individually into Perspex boxes (10 × 10 × 
10 cm) and the number of spontaneous pain behaviors (licks and flinches) was counted by an 
observer unaware of the treatments received for 10 min following injection of OD1 from 
video recordings.  
 
2.12 Molecular model of Df1a 
The three dimensional structure of Df1a was modeled using the NMR-derived structure of 
β/ω-theraphotoxin-Tp1a (ProTx-I, PDB code 2M9L) as template (Gui et al., 2014). Backbone 
fitting and energy minimization were performed using the Swiss-Model prediction algorithm 
(open source, http://swissmodel.expasy.org) (Arnold et al., 2006) and displayed using the 
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PyMOL Software package (DeLano, 2002). The model was validated by inspection of the 
Ramachandran plot (Lovell et al., 2003).  
 
2.13 Data analysis 
The data and statistical analysis comply with the recommendations on experimental design 
and analysis in pharmacology (Curtis et al., 2015). Curve fitting was achieved using 
GraphPad Prism Version 6 (GraphPad Software Inc, San Diego, CA, USA) using nonlinear 
regression with log[inhibitor] versus normalized response and variable Hill slope for dose-
responses, Boltzmann sigmoidal equation for voltage-dependence of activation and 
inactivation and exponential one-phase association for on and off-rate analysis. Data were 
represented as mean ± SEM of at least five independent experiments, unless otherwise stated. 
For the in vitro experiments, statistical significance was determined by paired t-test assuming 
equal variance. For the in vivo experiments, statistical significance was determined by 
ANOVA with Dunnett’s post-test. P < 0.05 was considered significant. 
 
2.14 Materials 
Cell culture reagents were from Gibco, Life Technologies Corporation (Carlsbad, CA, USA), 
unless otherwise stated. For the RP-HPLC, calcium influx assays, peptide synthesis and 
oxidative folding, electrophysiological assays and in vivo experiments, all reagents were from 
Sigma-Aldrich (St Louis, MO, USA) unless otherwise stated. 
 
2.15 Nomenclature of Targets and Ligands 
 
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS 
Guide to PHARMACOLOGY (Southan et al., 2016), and are permanently archived in the 
Concise Guide to PHARMACOLOGY 2015/16 (Alexander et al., 2015). 
 
3. Results 
 
3.1 Peptide toxin identification and chemical synthesis 
Fractionation of the Davus fasciatus venom (1 mg) using RP-HPLC revealed eight dominant 
peaks eluting from 20% to 40% solvent B (Figure 1A). Testing aliquots (10%) of 1-min 
fractions for activity in SH-SY5Y cells stimulated by co-addition of OD1 and veratridine 
revealed three fractions that strongly inhibited hNaV1.7 (Figure 1A, gray circles). MALDI-
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TOF MS analysis revealed that the peaks eluting at 30.8 and 32.2 min contained multiple 
peptides that proved difficult to separate and could not be definitively characterized (data not 
shown). The remaining fraction eluting at 36–37 min (33% B) contained a single major 
peptide with a monoisotopic mass of 4075.8 Da (Figure 1B). N-terminal Edman sequencing 
disclosed a novel 34-residue peptide that we named Df1a (μ-TRTX-Df1a). The peptide 
sequence had a calculated monoisotopic oxidized mass of 4076.8 Da, suggesting that it was 
C-terminally amidated in its native form (Figure 1C). Sequence comparisons revealed that 
Df1a belonged to the Family 2 of NaV-targeting spider toxins (NaSpTx), which is comprised 
of 33–41 residues peptides with hyper-stable ICK motifs that inhibit NaV, CaV and KV 
channels (Herzig & King, 2015; Klint et al., 2012). Sequence analysis revealed the highest 
identity with β/ω-TRTX-Tp1a (ProTx-I, 73%), ω-TRTX-Hhn1a (64%) and TRTX-Hh2a 
(61%) (Figure 1D).  
 
Chemical synthesis was used to generate the C-terminal amide and acid forms of Df1a 
(Figure 2A). Both native and synthetic Df1a-NH2, as well as synthetic Df1a-OH, eluted as a 
complex set of partially resolved peaks by analytical HPLC at 40C (Figure 2A) but as two 
peaks at 23C (Figure 2B). Comparable temperature-dependent dynamics have been reported 
previously for human β-defensins (Chino et al., 2006), while hanatoxin also elutes as two 
peaks, although temperature dependence was not reported (Takahashi et al., 2000). 
Importantly, all major peaks associated with synthetic Df1a-NH2 co-eluted with native Df1a, 
confirming the assigned sequence and that the native disulfide bond pairings had been 
achieved. In order to rapidly evaluate the activity of the synthetic Df1a over NaV channels, a 
FLIPR-based fluorescence assay was performed. Synthetic Df1a-NH2 was found to potently 
inhibit endogenous hNaV1.7 in SH-SY5Y cells (Figure 2C). Given their structural identity 
and functional activity, synthetic Df1a (sDf1a-NH2 and sDf1a-OH) was used for all 
subsequent characterization studies. 
 
3.2 Effect of Df1a on NaV channels and CaV3 
We evaluated the effect of Df1a on a range of voltage-gated ion channels by using automated 
whole-cell patch clamp to examine its effect on hNaV1.1–1.5, hNaV1.7, hCaV3.2 and hCaV3.3 
expressed in HEK 293 cells, and hNaV1.6 and hCaV3.1 expressed in CHO cells (Figure 3 A–
J, Supporting Information Table S1). Df1a-NH2 inhibited hNaV1.1–1.7 channels, with 
preference for hNaV1.2, hNaV1.3 and hNaV1.7. The C-terminal acid form of Df1a (Df1a-OH) 
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lost potency at all NaV subtypes compared the C-terminal amide form, especially at hNaV1.7, 
to be hNaV1.2, hNaV1.3 and hNaV1.6 preferring. The effect of Df1a was also investigated by 
two-electrode voltage clamp in Xenopus laevis oocytes expressing hNaV1.7 showing Df1a-
NH2 inhibited this channel with more potency compared to Df1a-OH, and displayed IC50 
values of up to 8.5-fold difference compared to the automated whole-cell patch clamp in 
mammalian cells (Supporting Information Fig. S1A and S1C). Furthermore, the effect of 
ProTx-I, a spider toxin also belonging to the NaSpTx Family 2, was investigated on hNaV1.7 
by two-electrode voltage clamp and automated whole-cell patch clamp. ProTx-I inhibited 
hNaV1.7 currents with similar IC50 values in both electrophysiology systems (Supporting 
Information Fig. S1E and Fig. S2A). Df1a-NH2 also inhibited the CaV3 channels responses, 
with preference for hCaV3.1 and hCaV3.3. This inhibition was less potent in the C-terminal 
acid form of Df1a for all CaV3 subtypes. The IC50 values and Hill slope for each hNaV and 
hCaV3 subtypes in the presence of Df1a are described in Supporting Information Table S1. 
The number of independent experiments are indicated in Supporting Information Table S1.  
 
3.3 Effect of Df1a on activation and inactivation of hNaV channels 
 Most spider toxins that inhibit NaV channels are gating modifiers that alter the voltage-
dependence of channel gating (Catterall et al., 2007). In order to investigate the mode of 
action of Df1a, we examined its effect on the voltage-dependence of NaV channel activation 
and steady state-inactivation using automated whole-cell patch clamp using HEK293 cells 
expressing the hNaV1.1–1.5 and 1.7, and CHO cells expressing hNaV1.6. We found that both 
Df1a-NH2 and Df1a-OH shifted the voltage-dependence of activation and of steady-state fast 
inactivation of hNaV subtypes to more hyperpolarizing or depolarizing potentials when 
applied at respective IC50 concentration for each NaV channel subtype (Figure 4). More 
specifically, Df1a considerably altered the voltage-dependence of activation of hNaV1.2 
(ΔV50 (mV) –6.9  1.3 for Df1a-OH), hNaV1.3 (ΔV50 (mV) 10.6  1.6 and 5.6  1.3 for Df1a-
NH2 and OH, respectively), hNaV1.5 (ΔV50 (mV) –7.2  2.1 for Df1a-OH) and hNaV1.7 (ΔV50 
(mV) 10.7  1 and 5.3  1.5 for Df1a-NH2 and OH, respectively) (Figure 4 B, C, E and G). 
Moreover, Df1a shifted the voltage-dependence of steady-state fast inactivation of hNaV1.1 
(ΔV50 (mV) –19.1  2.6 for Df1a-NH2), hNaV1.2 (ΔV50 (mV) –9.1  2.2 and –5.3  1.3 for 
Df1a-NH2 and OH, respectively), hNaV1.6 (ΔV50 (mV) –6.5  0.98 and –8  2.6 for Df1a-
NH2 and OH, respectively) and hNaV1.7 (ΔV50 (mV) –16.9  2.9 and –17.5  2.3 for Df1a-
NH2 and OH, respectively) (Figure 4A, B, D and F). In striking contrast, Df1a shifted the 
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steady-state inactivation for hNaV1.3 to more depolarizing potentials (ΔV50 (mV) 9.6  1.5 
and 7.9  2.3 for Df1a-NH2 and OH, respectively) (Figure 4C). ΔV50 values not reported 
were between –5 mV and +5mV. There was a general trend for Df1a to shift both voltage-
dependence of activation and of steady-state fast inactivation of the hNaV subtypes to more 
hyperpolarizing potentials, with exemptions found for the subtypes hNaV1.3 and hNaV1.7 
(Figure 4H). The effect of Df1a on activation and inactivation of hNaV1.7 was also 
investigated by two-electrode voltage clamp in Xenopus laevis oocytes (Supporting Fig. S1B 
and S1D). No effect in the voltage-dependence of activation and inactivation of hNaV1.7 was 
observed in the presence of Df1a-NH2 and Df1a-OH when two-electrode voltage clamp in 
oocytes was used. A similar effect in hNaV1.7 was observed in the presence of ProTx-I, 
where there were no significant changes in the voltage-dependence of activation and 
inactivation using both two-electrode voltage clamp and automated whole-cell patch clamp 
electrophysiology systems (Supporting Fig. S1F and Fig. S2B). 
 
A slowing in the fast inactivation of NaV channels was observed for hNaV1.1, hNaV1.3 and 
hNaV1.5 in the presence of Df1a-NH2 and Df1a-OH (Figure 5). Representative traces show 
slowed fast inactivation occurring simultaneously with peak current inhibition in the presence 
of Df1a at the respective IC50 concentrations for each channel subtype (Figure 5A). The 
slowing in fast inactivation was fully inhibited in the presence of 1 μM Df1a, along with peak 
current. The inactivation decay time constant (τ) was calculated, revealing this toxin slows 
the inactivation of NaV1.1 by 2.1 and 2.3-fold, NaV1.3 by 36.2 and 9-fold and NaV1.5 by 2.1 
and 1.8-fold in the presence of Df1a-NH2 and Df1a-OH, respectively. The remaining fraction 
of currents was calculated at 20 ms after 0 mV application, showing NaV1.3 with the highest 
fraction of persistent currents, followed by NaV1.5 and NaV1.1. (Figure 5B–D).  
 
3.4 Kinetics of Df1a inhibition and current recovery in hNaV1.3 and hNaV1.7 
Association/dissociation rates and reversibility can impact considerably on the therapeutic 
potential of ion channel modulators. Thus, we used automated whole-cell patch clamp 
electrophysiology to measure on- and off-rates for Df1a inhibition of hNaV1.3 and hNaV1.7. 
Current inhibition and recovery were estimated following application of the amidated and 
acid forms of Df1a (Figure 6A-H, Table 1). The association rates for hNaV1.3 (Kon) were 
slower for Df1a-NH2 compared to Df1a-OH at IC50 values (τ (min) 3.92 and 1.51 for Df1a-
NH2 and Df1a-OH, respectively) (Figure 6A), while for hNaV1.7 the association rates (Kon) 
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were faster for the Df1a-NH2 compared to Df1a-OH at IC50 values (τ (min) 0.64 and 3.06 for 
Df1a-NH2 and Df1a-OH, respectively) (Figure 6B). When applied at concentration ten times 
the respective IC50 value, Df1a-OH showed faster association rates for both hNaV1.3 and 
hNaV1.7. Current traces after 2.5 min incubation with Df1a showed a persistent slowing in 
fast inactivation for hNaV1.3, which was absent in hNaV1.7 (Figure 6C–F). The inhibition of 
hNaV1.3 and hNaV1.7 was quasi-irreversible for Df1a-NH2, while for Df1a-OH the inhibition 
was quasi-irreversible for hNaV1.7 but reversible for hNaV1.3 (Figure 6G and H). The 
irreversibility of Df1a was tested using a –80 mV holding potential, and more hyperpolarized 
holding potentials should be tested in the near future to further evaluate irreversibility of this 
toxin over NaV channels. 
 
3.5 NaV1.7 sites interacting with Df1a 
We used a panel of previously described hNaV1.7/rKv2.1 S3-S4 paddle chimeras (Klint et al., 
2015) to map the binding site for Df1a on hNaV1.7 (Figure 7). The acid and amide forms of 
Df1a had no effect on the DI chimera or wild-type rKV2.1 at 1 μM concentration, and they 
only partially inhibited currents from the DIII and DIV chimeras. In contrast, 1 μM Df1a-
NH2 and Df1a-OH significantly inhibited currents from the DII chimera. Thus, our data 
indicate that Df1a primarily interacts with the DII voltage sensor of hNaV1.7, with weaker 
interactions with VSD III and IV. 
 
3.6 Df1a is analgesic in a mouse model of pain 
In order to evaluate the potential of Df1a to reverse peripheral pain in vivo, we use an OD1-
induced pain model. Intraplantar injection of OD1, a scorpion toxin that preferentially 
potentiates NaV1.4, NaV1.6 and NaV1.7 (Durek et al., 2013), causes rapid development of 
spontaneous pain in mice as evidenced by flinching and licking of the affected hind paw 
(Cardoso et al., 2015; Deuis et al., 2016). Intraplantar injection of 10 μM Df1a-NH2 or Df1a-
OH (400 pmoles in a 40 μl injection) significantly reduced spontaneous pain behavior (Figure 
8; OD1, 102 ± 4 flinches 10 min
–1
; 10 μM Df1a-NH2, 56 ± 7 flinches 10 min
–1
; 1 μM Df1a-
OH, 73 ± 8 flinches 10 min
–
1; 10 μM Df1a-OH, 30 ± 6 flinches 10 min–1, P < 0.05). No 
significant reduction in the pain behavior was observed when Df1a-NH2 or Df1a-OH was 
administered at 1 μM (40 pmoles in a 40 μl injection). Data are presented as mean ± SEM of 
n = 5 mice per group treated with Df1a and n = 12 mice in the control group. 
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3.7 Structure analysis of Df1a 
The 3D structure of μ-TRTX-Df1a was modeled using the structure of β/ω-theraphotoxin-
Tp1a (ProTx-I, PDB code 2M9L) as a template (Gui et al., 2014) (Figure 9A). The model 
obtained had a GMQE score of 0.91, with 82% of residues in the favored region of the 
Ramachandran plot. The structural model revealed Df1a adopts an ICK fold that is organized 
into two distinct faces; a hydrophobic patch surrounded by charged residues lies opposite a 
face comprised primarily of neutral hydrophilic residues face (Figure 9B). The hydrophobic 
patch is dominated by aromatic residues in Df1a, including the central W4, F5, W27 and 
W30 residues and the peripheral W32 and F34 residues. This is reminiscent of the 
hydrophobic patch present in the ProTx-I (Y4, W5, W27, W30 and F34), although there are 
significant differences including E17K, Q26G and W32G (Figure 9C). Nevertheless, the 
structural data suggest that these toxins share similar binding properties to NaV1.7. 
 
4. Discussion 
 
Spider venoms have proven to be a rich source of peptides ligands that modulate NaV 
channels (King, 2011). Their ability to target ion channels at allosteric binding sites often 
enhances target selectivity and opens up opportunities for new ion channel therapeutics. In 
the present work, we report the discovery and characterization of a new NaV and CaV3 
channel inhibitor named Df1a from the tarantula Davus fasciatus. Df1a belongs to NaSpTx 
Family 2, whose members contain an ICK motif and highly conserved N and C-termini. The 
closest orthologue of Df1a is the NaV and CaV3 channel inhibitor ProTx-I (Middleton et al., 
2002). However, ProTxI causes a reduction in peak current without altering channel 
inactivation, whereas Df1a has the dual effect of reducing peak current and slowing fast 
inactivation of some NaV channel subtypes. 
 
Electrophysiology using mammalian cells revealed that Df1a inhibits hNaV with a rank order 
of potency 1.7>1.2>1.3>1.6>1.1>1.4>1.5, and hCaV3 with a rank order 3.1>3.3>3.2. 
Interestingly, C-terminal amidation of Df1a increased potency by 1.7 to 4-fold for hNaV1.1 to 
hNaV1.6, 1.2 to 8.7-fold for hCaV3.1 to hCaV3.3, and remarkably by 32-fold for hNaV1.7. The 
effect on hNaV1.7 was also observed using two-electrode voltage clamp in oocytes; in this 
system C-terminal amidation increased potency against NaV1.7 by 22-fold. C-terminal 
amidation has been reported to significantly increase the potency of other NaSpTx peptides. 
The amidated form of huwentoxin-IV, a toxin isolated from the spider Haplopelma schmidti, 
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is 42-fold more potent against NaV1.7 (Sermadiras et al., 2013). The C-terminally amidated 
form of ProTx-III, a toxin that we recently isolated from the spider Thrixopelma pruriens, is 
4.6-fold more potent against NaV1.7, and 8.9 and 3.5-fold more potent against NaV1.1 and 
NaV1.3, respectively (Cardoso et al., 2015). Although these peptides do not display favorable 
selectivity for key ion channels involved in complex disorders, the remarkable increase in 
potency of their C-terminal amide forms is important for the rational development of peptide 
drugs that target voltage-gated ion channels. 
 
Among the ion channels studied in this work, hNaV1.3, hNaV1.7 and hCaV3.2 are known to 
be involved in pain disorders. hNaV1.3 is upregulated in dorsal root ganglion neurons during 
chronic constriction nerve injury and following axotomy (Dib-Hajj et al., 1999; Waxman et 
al., 1994). Lack of NaV1.7 function induces insensitivity to pain (Cox et al., 2006), and a 
monoclonal antibody against NaV1.7 suppresses inflammatory and neuropathic pain in mice 
(Lee et al., 2014). Altered T-type Ca
2+
 currents are involved in somatic and visceral pain 
signaling, and the hyperalgesia induced by L-cysteine was reported to be present in wild-type 
but not CaV3.2-knockout mice (Maeda et al., 2009; Nelson et al., 2007). These studies 
emphasize the potential of Df1a as a tool peptide to help guiding the development of novel 
drugs that simultaneously target NaV and CaV channels involved in chronic pain states. 
 
Patch-clamp studies revealed that Df1a alters the voltage-dependence of activation and 
inactivation of hNaV channels. Other spider toxins belonging to NaSpTx2 and which alter the 
gating properties of NaV channels are β-TRTX-Cm2a and μ-TRTX-Cj1a (Bosmans et al., 
2006; Chen et al., 2009). Curiously, Df1a also slowed fast inactivation of hNaV1.1, hNaV1.3 
and hNaV1.5. A similar effect was observed for the spider toxin JZTX-XI, which slowed fast 
inactivation of TTX-R and TTX-S sodium channels (Liao et al., 2006; Tao et al., 2016), and 
for the spider toxin ProTx-II at NaV1.2 to NaV1.5 and NaV1.7 channels (Xiao et al., 2010). 
However, ProTx-II induces persistent currents in hNaV1.7 at saturating concentrations, while 
Df1a is a full inhibitor of NaV channel currents irrespective of subtype. Interestingly, Df1a 
showed no changes in the voltage-dependence of activation and inactivation of hNaV1.7 using 
two-electrode voltage clamp in oocytes. Differences in membrane composition between 
mammalian cells and oocytes that potentially influence how spider toxins bind to the NaV1.7 
channel could explain the effects observed (Henriques et al., 2016). Furthermore, for the two-
electrode voltage clamp studies reported here, no β subunit was co-expressed with NaV1.7, 
which could alter gating properties as well as toxin affinity to the channel. It was previously 
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demonstrated that in oocytes, in the absence of the β1 subunit, fast inactivation of NaV is 
slowed and steady-state inactivation altered by a ΔV50 of 6 mV (Shcherbatko et al., 1999). In 
this present study, the ΔV50 of NaV1.7 steady-state inactivation observed in the presence and 
absence of the β1 subunit was 12 mV, which confirms the slowing in inactivation previously 
observed. Furthermore, in studies in which NaV1.2 was expressed in oocytes, the spider toxin 
ProTx-II completely lost affinity to this channel in the presence of the β4 subunit, while the 
scorpion toxin TsVII showed potent activity over NaV1.2 only in the absence of β4 (Gilchrist 
et al., 2013). 
 
To further investigate the site of action of Df1a, we used a panel of hNaV1.7/KV2.1 chimeras 
(Klint et al., 2015). These experiments revealed that Df1a preferentially interacts with the DII 
voltage sensor of hNaV1.7, and to a less extent with the DIII and DIV voltage sensors. The 
data also revealed that Df1a has no effect on KV2.1, although its closest orthologue ProTx-I 
potent inhibits this potassium channel (Middleton et al., 2002). Previous reports have shown 
that inhibition of NaV1.7 by spider toxins is mediated through interactions with the DII 
voltage sensor (Klint et al., 2015), whereas toxins that slow fast inactivation primarily 
interact with the DIV voltage sensor (Campos et al., 2008; Mitrovic et al., 2000; Rogers et al., 
1996; Tao et al., 2016; Xiao et al., 2010). Similar studies performed with ProTx-II 
demonstrated interactions of this toxin with the DI, DII and DIV voltage sensors of NaV1.2 
(Bosmans et al., 2008), suggesting that DII and DIV interactions mediate the dual modulatory 
effects observed for both Df1a and ProTx-II. Df1a does not affect fast inactivation of 
hNaV1.7, consistent with its more robust binding to the DII voltage sensor of this channel. In 
contrast, since Df1a does slow fast inactivation of NaV1.1, NaV1.3 and NaV1.5, we speculate 
that the toxin interacts more avidly with the DIV voltage sensor in these NaV channel 
subtypes. Although the chimeric channels provide useful insights into the binding sites for 
Df1a on NaV channels, these interactions might differ among NaV channel subtypes and/or in 
the complete NaV voltage-sensor constructs. 
 
Modeling of the Df1a structure revealed an ICK motif typical of spider toxins gating-
modifiers (Klint et al., 2012). Furthermore, the structure of Df1a displayed surface 
similarities with the structure of ProTx-I (Gui et al., 2014) and three other spider toxins 
belonging to the NaSpTx Family 2 and inhibitors of KV (κ-TRTX-Gr1a and κ-TRTX-Scg1a) 
and CaV (ω-TRXT-Gr1a) (Takahashi et al., 2000; Takeuchi et al., 2002; Wang et al., 2004). 
These displayed a conserved large hydrophobic patch surrounded by positively charged 
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residues which is potentially involved in the interactions with the hydrophobic core of the cell 
membrane and the S3-S4 linker regions of the voltage-gated ion channels. The 
pharmacophore for ProTx-I interaction with hNaV1.2 was established by alanine-scan (Gui et 
al., 2014), from which the key residues identified were found to be identical in Df1a, 
suggesting that these toxins possibly share a similar pharmacophore for NaV channels. 
Further studies are required to elucidate pharmacophore for Df1a as well as identify residues 
that might enhance selectivity towards key channels subtypes and its potential as a lead for 
treating NaV and CaV3-related disorders. 
 
Finally, given the important role of NaV channels in nociception, we tested the analgesic 
efficacy of Df1a in a rodent pain model in which nocifensive behavior is elicited by 
intraplantar administration of the NaV activator OD1 (Cardoso et al., 2015; Deuis et al., 2016; 
Durek et al., 2013). Intraplantar administration of Df1a-NH2 and Df1a-OH reduced the 
nocifensive behavior by 42% and 71%, respectively, suggesting that Df1a can effectively 
inhibit OD1 induced pain at peripheral sensory nerve endings in the skin. Although we have 
evidence Df1a inhibits NaV and CaV3 channels involved in peripheral sensory pain, the exact 
targets of the observed analgesic effect remain to be fully elucidated. Interestingly, the Df1a 
C-terminal acid was less potent than the amide form at the human NaV isoform co-expressed 
with β1, but more effective at reducing pain behaviours in a rodent pain model. This effect 
could be related to differences between the human and rodent ion channel isoforms and/or 
due to distinct expression and combinations of auxiliary β subunits in vivo, which could lead 
to altered sensitivities to Df1a (Gilchrist et al., 2013; Isom, 2001). Assessment of the 
analgesic potential of Df1a in disease-specific pain models will provide additional insight 
into the clinical potential of this peptide for the treatment of chronic pain. 
In conclusion, we have characterized a new spider toxin named μ-TRTX-Df1a. Df1a is a 
potent NaV and CaV3 channel inhibitor that in addition to shifting the voltage-dependence of 
activation and inactivation produces a prominent slowing in fast inactivation at specific NaV 
channels subtypes. Channel inhibition in vitro was enhanced by C-terminal amidation of 
Df1a, but the C-terminal acid form showed better analgesic properties in vivo. The in vivo 
analgesic efficacy of Df1a suggests it might be a useful lead for the development of 
analgesics targeting NaV-induced pain. 
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Table 1. Kinetics of current inhibition and recovery of hNaV1.3 and hNaV1.7 after 
application of μ-TRTX-Df1a.  
Channel   Toxin Concentration Kon Koff Kd 
  
sDf1a-NH2 
 
sDf1a-OH 
nM nM
-1
s
-1
  s
-1
  nM 
hNaV1.3 3 1.4 ± 0.1 x 10
-3
  0 0 
 30 2.9 ± 0.7 x 10
-4
 ND ND 
 10 1.5 ± 0.2 x 10
-3
 8.8 ± 1.5 x 10
-3
 12.5 ± 1.3 
 100  1.6 ± 0.3 x 10
-4
  ND  ND 
hNaV1.7 sDf1a-NH2 
 
sDf1a-OH 
2 1.3 ± 0.2 x 10
-2
  0 0 
 20 6.3 ± 1.3 x 10
-4
  ND ND 
 60 9.0 ± 1.2 x 10
-5
  0 0 
  600  2.1 ± 0.2 x 10
-5
  ND ND 
sDf1a-NH2 was applied at 3 and 30 nM for hNaV1.3 and 2 and 20 nM for hNaV1.7, while 
sDf1a-OH was applied at 10 and 100 nM for hNaV1.3 and 60 and 600 for hNaV1.7, and 
sodium currents measured. The kinetics of inhibition and recovery of inhibition were 
determined from the I/Imax as function of time from traces shown in Figures 7A–H fitted to a 
single exponential fit. Values are from n = 5 independent experiments (mean ± SEM). ND = 
Not determined. 
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Figure legends 
 
Figure 1. Venom fractionation, activity screening on NaV1.7, mass spectrometry and amino 
acids analysis of active fraction 36. (A) RP- HPLC of the Davus fasciatus crude venom (1 
mg) was performed in Vydac218TP C18 using a three-step gradient of acetonitrile/0.05% 
trifluoroacetic acid (5-10% B for 5 min, 20-40% B for 40 min and 40-80% B for 5 min). 
Fractions were collected at 0.7 mL minute
–1
 and screened for NaV1.7 inhibition using 
Calcium dye and FLIPR
Tetra
 instrument. Fractions eluted at 30.8, 32.2 and 36 min showed 
strong NaV1.7 inhibition (orange shaded fractions). (B) MALDI-TOF mass spectrometry of 
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fraction 36 showing single predominant mass of 4075.8 Da. (C) Sequence identification and 
analysis of μ-TRTX-Df1a. Edman degradation analysis of the native toxin revealed a peptide 
with 34 residues containing 6 cysteines. The difference of masses between the native Df1a 
and predicted mass of the amino acids sequence revealed by Edman degradation indicates the 
presence of a C-terminal amidation in the native peptide. Sequence alignment of peptides 
toxins showing at least 47% identity in their amino acids sequence with Df1a. Identical 
residues are shown in blue and cysteine scaffold in red. The % of identity is shown relative to 
Df1a, and the activity reported for each peptide toxin is described in the far right column 
according to data sourced from the ArachnoServer database (Herzig et al., 2011). Asterisks 
denote C-terminal amidation. Df1a showed its highest identity with the toxin β/ω-TRTX-
Tp1a (ProTx-I) isolated from the tarantula Thrixopelma pruriens (Middleton et al., 2002). 
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Figure 2. Comparison of the retention time of native μ-TRTX-Df1a and synthetic Df1a-NH2 
and Df1a-OH in HPLC. (A) Analytical RP-HPLC chromatograms of native amidated Df1a, 
synthetic Df1a-NH2 and synthetic Df1a-OH. RP-HPLC was performed on a Shimadzu 
LC20AT system using a Thermo Hypersil GOLD C18 column (2.1 x 100 mm) heated at 
40C. Peptides were eluted using a gradient of 5–50% B over 45 min with a flow rate of 0.3 
mL min
–1
. Native Df1a and synthetic Df1a-NH2 eluted both at 33.2 (minor peak) and 35.1 
(major peak) min, while synthetic Df1a-OH eluted at 34.1 (minor peak) and 35.9 (major 
peak) min. (B) Analytical HPLC trace showing synthetic Df1a-NH2 at 23C. Lowering the 
temperature produced a deconvolution of the chromatogram resulting in only two peaks and 
disappearance of the unresolved portion between them observed at 40C. (C) Activity of 
synthetic sDf1a-NH2 and sDf1a-OH over hNaV1.7 in SH-SY5Y cells determined using a 
fluorescent assay. The IC50 for hNaV1.7 inhibitions were (in μM) 0.117 ± 0.006 and 1.24 ± 
0.30 for sDf1a-NH2 and sDf1a-OH, respectively. Data are presented as mean ± SEM, n = 9 
independent experiments performed in 3 different days. 
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Figure 3. Inhibition of hNaV and hCaV3 subtypes by μ-TRTX-Df1a measured by automated 
patch clamp electrophysiology in QPatch 16X. Holding potential was –80 mV for hNaV and –
90 mV for hCaV3. Na
+
 currents were elicited by 20 ms voltage steps to 0 mV from a –120 
mV conditioning pulse applied for 200 ms, and Ca
+2
 currents were elicited by 60 ms voltage 
steps to -30 mV from a –120 mV conditioning pulse applied for 60 ms. Representative 
concentration-response curves for inhibition of (A) hNaV1.1, (B) hNaV1.2, (C) hNaV1.3, (D) 
hNaV1.4, (E) hNaV1.5, (F) hNaV1.6, (G) hNaV1.7, (H) hCaV3.1, (I) hCaV3.2 and (J) hCaV3.3. 
The IC50 values calculated using I/Imax values and non-linear regression were (in nM) 14.3 ± 
0.1 (n = 5) and 30.7 ± 2.2 (n = 6) for hNaV1.1, 1.9 ± 0.5 (n = 5) and 3 ± 1.4 (n = 5) for 
hNaV1.2, 3 ± 0.7 (n = 5) and 10 ± 1 (n = 8) for hNaV1.3, 24 ± 1.8 (n = 5) and 53.6 ± 12 (n =6) 
for hNaV1.4, 45.3 ± 6.8 (n = 5) and 125.6 ± 21 (n = 5) for hNaV1.5, 7.6 ± 0.4 (n = 5) and 23 ± 
2.9 (n = 7) for hNaV1.6, 1.9 ± 0.08 (n = 6) and 60.5 ± 6.1 (n = 6) for hNaV1.7, 44.6 ± 5.8 (n = 
8) and 216 ± 28.1 (n = 7) for hCaV3.1, 253 ± 45.7 (n = 6) and 371 ± 48.8 (n = 6) for hCaV3.2 
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and 48.4 ± 7.2 (n = 5) and 460 ± 43.7 (n = 7) for hCaV3.3, under application of sDf1a-NH2 
and sDf1a-OH, respectively. Data are represented as mean ± SEM from described n for 
independent experiments, one cell was considered per independent experiment. 
  
  
This article is protected by copyright. All rights reserved. 
 
  
This article is protected by copyright. All rights reserved. 
Figure 4. Modulation of the voltage dependence of hNaV channels activation and inactivation 
gating in the presence of μ-TRTX-Df1a. Data (mean ± SEM, n = 5, one cell was considered 
per independent experiment) for (A) hNaV1.1, (B) hNaV1.2, (C) hNaV1.3, (D) hNaV1.4, (E) 
hNaV1.5, (F) hNaV1.6 and (G) hNaV1.7 are plotted as G/Gmax or I/Imax. Cells were held at –80 
mV. μ-TRTX-Df1a C-terminal amide and acid were applied at respective IC50 concentration 
for each NaV channel subtype as described in Figure 3 and Supporting Information Table S1. 
Steady state kinetics were estimated by currents elicited at 5 mV increment steps ranging 
from –110 to +80 mV. Conductance was calculated using G = I/(V–Vrev) in which I, V and 
Vrev are the current value, membrane potential and reverse potential, respectively. The 
voltage-dependence of fast inactivation was estimated using a double-pulse protocol where 
currents were elicited by a 20 ms depolarizing potential of 0 mV following a 500 ms pre-
pulse at potentials ranging from –130 to –10 mV with 10 mV increments. Steady-state 
activation and inactivation V50 were determined by the Boltzmann equation. Both C-terminal 
acid and amide forms of sDf1a applied at respective IC50 concentrations modified the gating 
properties of hNaV channels by shifting the voltage-dependence of activation and steady-state 
inactivation to more hyperpolarizing or depolarizing potentials. The ΔV50 was calculated, 
showing most of the voltage shifts towards more hyperpolarizing potentials, except for 
hNaV1.3 and hNaV1.7 that had some of these shifts to more hyperpolarizing potentials (Figure 
4H). 
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Figure 5. μ-TRTX-Df1a slows fast inactivation of hNaV1.1, hNaV1.3 and hNaV1.5 along with 
peak current reduction under application of sDf1a-NH2 or sDf1a-OH. The same effect is not 
observed in other hNaV subtypes tested, which presented only peak current reduction under 
application of sDf1a-NH2 or sDf1a-OH (data not shown). Cells were held at –80 mV and Na
+
 
currents were elicited by 20 ms voltage steps to 0 mV from a –120 mV conditioning pulse 
applied for 200 ms. (A) Representative traces of hNaV1.1, hNaV1.3 and hNaV1.5 in the 
presence of sDf1a-NH2 and sDf1a-OH. Cells were applied with the correspondent IC50 (black 
traces) and 1 μM sDf1a (gray trances) for each NaV subtype and incubated for 5 min before 
depolarization at 0 mV. No toxin controls are represented in dashed traces. Current traces 
showing the slowing in fast inactivation are featured by arrows. The slowing of fast 
inactivation at 5 ms after application of 0 mV was plotted against the log scale of various 
concentrations of Df1a, and maximum slowing in inactivation evaluated. (B-D) hNaV1.1, 
hNaV1.3 and hNaV1.5 inactivation decay time constant (τ) and percentage of remaining 
currents were calculated in the presence of respective IC50 concentrations of Df1a for each 
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channel subtype. Blue traces represent the time constant (τ) in the presence of Df1a-NH2 and 
red traces in the presence of Df1a-OH. Remaining currents (%) are described in the far right 
of the x-axis at each graph. Remarkable slowing of fast inactivation is observed for the 
subtype NaV1.3 in the presence of Df1a, which also displayed the highest percentage of 
remaining currents at 20 ms. Data are presented as mean  SEM from n ≥ 5 independent 
experiments for each ion channel assayed, one cell was considered per independent 
experiment (see Supporting Information Table S1). 
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Figure 6.  Kinetics of hNaV currents inhibition and recovery in the presence of μ-TRTX-
Df1a. Cells were maintained at a holding potential –80 mV and Na+ currents elicited by 20 
ms voltage steps to 0 mV from a –120 mV conditioning pulse applied for 200 ms. (A) For on-
rates, Na
+
 currents were recorded every 15 seconds during 15 min after toxin addition. The 
on-rates for hNaV1.3 were 4.34 and 2.03 min at 3 and 30 nM sDf1a-NH2, respectively, and 
1.14 and 1.13 min at 10 and 100 nM sDf1a-OH, respectively. (B) For hNaV1.7, the on-rates 
were 0.64 and 1.32 min at 2 and 20 nM sDf1a-NH2 and 3.06 and 1.32 min at 60 and 600 M 
sDf1a-OH, respectively. (C-F) Representative Na
+
 current traces after 2.5 min incubation 
with Df1a along to consecutive pulses of 0 mV with 15 seconds intervals. A persistent 
slowing in fast inactivation associated to peak current reduction was observed for hNaV1.3 in 
the presence of (C) 3 nM sDf1a-NH2 and (D) 10 nM sDf1a-OH, while for hNaV1.7, only peak 
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reduction is observed in the presence of (E) 2 nM sDf1a-NH2 and (F) 60 nM sDf1a-OH. (G-
H) For the wash-out of sDf1a-NH2 and sDf1a-OH over hNaV1.3 and hNaV1.7, cells were 
incubated for 10 min with Df1a and Na
+
 currents assessed at 5 min intervals during saline 
washes. The inhibition by sDf1a-OH at IC50 concentration is reversible only in the hNaV1.3 
subtype, while for sDf1a-NH2 over hNaV1.3 and hNaV1.7, and sDf1a-OH over hNaV1.7 the 
inhibition remained quasi-irreversible under applied experimental conditions at up 50 min 
recording. The Kon, Koff and Kd were calculated using Kd = Koff/Kon (nM), where Koff = 1/τoff 
(s
-1
) and Kon = (1/τon -Koff)/[toxin] (nM
–1
S
–1
). Data are presented as mean ± SEM, n = 5 
independent experiments for each condition assayed, one cell was considered per independent 
experiment. 
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Figure 7. Binding sites of μ-TRTX-Df1a over hNaV.7. Chimeras hNaV1.7/rKV2.1 containing 
the paddles S3-S4 from DI-DIV from NaV1.7 were used to explore the binding site of Df1a 
over NaV1.7. Potassium currents elicited by depolarization to +70 mV. The currents are 
shown before and after addition of 1 μM Df1a toxin. sDf1a (both C-terminally acid and 
amide) preferentially binds to S3-S4 loop region in DII of NaV1.7, followed by DIII and DIV. 
Df1a (C-terminally acid and amide) had no effect on wild-type rKV2.1 at up to 1 μM. Data 
are from n = 5 independent experiments for each condition assayed, one oocyte was 
considered per independent experiment. 
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Figure 8.   Antinociceptive effects of μ-TRTX-Df1a. (A) Intraplantar injection of the NaV1.7 
activator OD1 (300 nM) led to rapid development of nocifensive behavior in mice. This 
spontaneous pain behavior, measured by the number of paw licks and flinches, was 
attenuated in a concentration dependent manner by co-administration of sDf1a-OH at 1 and 
10 μM, and sDf1a-NH2 at 10 μM but not at 1 μM. Data are presented as mean ± SEM of n = 
5 mice per group treated with Df1a and n = 12 mice in the control group, *P < 0.05. 
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Figure 9. Molecular modeling and structural features of μ-TRTX-Df1a. The three 
dimensional structure of Df1a was calculated using the NMR structure of β/ω-theraphotoxin-
Tp1a (ProTx-I) (Gui et al., 2014). (A) Cartoon model showing beta-sheet (cyan) and Cys-
bridges (red) of a typical ICK peptide. (B) Surface representation of Df1a structure with 180° 
rotation shown in cyan: negatively charged, blue: positively charged and red: hydrophobic 
residues (aromatics). Residues present in these regions are labeled (E1, R3, E17, H18, K24, 
W32 and F34). (C) Comparison of the structures of Df1a and ProTx-I. Highlighted in orange 
and cyan are the differences in amino acids residues between these toxins, respectively. 
These residues are W4Y, F5W, G11A, E17K, H22S, K24R, Q26G, W32G, S33T for Df1a 
and ProTx-I, respectively, and S35 present only in ProTx-I. Structures are shown in two 
orientations, rotated by 180°. 
